Profile data is unavailable for this security.
About the company
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
- Revenue in USD (TTM)257.55m
- Net income in USD11.95m
- Incorporated2007
- Employees134.00
- LocationEagle Pharmaceuticals Inc50 Tice Boulevard, Suite 315WOODCLIFF LAKE 07677United StatesUSA
- Phone+1 (201) 326-5300
- Fax+1 (302) 655-5049
- Websitehttps://www.eagleus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hcw Biologics Inc | 3.93m | -27.39m | 41.23m | 45.00 | -- | 4.72 | -- | 10.50 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 41.45m | 23.00 | -- | -- | -- | 14.71 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| NKGen Biotech Inc | -100.00bn | -100.00bn | 41.56m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Clene Inc. | 620.00k | -48.81m | 42.25m | 82.00 | -- | 9.91 | -- | 68.15 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 43.08m | 82.00 | -- | 0.4339 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Eyenovia Inc | 8.78k | -32.44m | 43.53m | 57.00 | -- | 21.06 | -- | 4,957.58 | -0.7448 | -0.7448 | 0.0002 | 0.0384 | 0.0003 | -- | 0.008 | 154.04 | -116.94 | -80.31 | -190.14 | -117.70 | 0.00 | -- | -369,519.70 | -680.95 | 0.6645 | -16.03 | 0.8914 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 43.55m | 14.00 | -- | 0.915 | -- | 2.29 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 44.20m | 75.00 | -- | 0.4886 | -- | 1.85 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 44.92m | -- | -- | 3.18 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 45.06m | 134.00 | 3.81 | 0.1803 | 1.38 | 0.175 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 46.03m | 29.00 | -- | 5.32 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Aligos Therapeutics Inc | 13.79m | -99.59m | 46.08m | 67.00 | -- | 0.7771 | -- | 3.34 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Kronos Bio Inc | 7.59m | -116.39m | 47.47m | 61.00 | -- | 0.3466 | -- | 6.26 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Inotiv Inc | 552.74m | -71.29m | 48.57m | 1.96k | -- | 0.2338 | -- | 0.0879 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 48.66m | 50.00 | -- | -- | -- | 48.20 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Eagle Pharmaceuticals Inc's reporting currency: US Dollar USD
47.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.26m | 9.69% |
| AIGH Capital Management LLCas of 31 Mar 2024 | 1.19m | 9.14% |
| AQR Capital Management LLCas of 31 Mar 2024 | 879.07k | 6.77% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 735.39k | 5.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 616.53k | 4.75% |
| LSV Asset Managementas of 31 Mar 2024 | 334.16k | 2.57% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 333.85k | 2.57% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 323.63k | 2.49% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 278.12k | 2.14% |
| J. Goldman & Co. LPas of 31 Mar 2024 | 258.70k | 1.99% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
